Ian Lee

Dr. Ian Lee

Henry Ford Health System

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
TCTimothy F. Cloughesy
Timothy F. Cloughesy
JLJoseph Landolfi
Joseph Landolfi
DHDaniel J. Hogan
Daniel J. Hogan
SBStephen Bloomfield
Stephen Bloomfield
BCBob Carter
Bob Carter
MVMichael Vogelbaum
Michael Vogelbaum
Toca 511 (vocimagene amiretrorepvec) is an investigational nonlytic, retroviral replicating vector (RRV) that delivers a yeast cytosine deaminase, which converts subsequently administered courses of the investigational prodrug Toca FC (extended-release 5-fluorocytosine) into the antimetabolite 5-fluorouracil. Forty-five subjects with recurrent or progressive high-grade glioma were treated. The end points of this phase 1, open-label, ascending dose, multicenter trial included safety, efficacy, and molecular profiling; survival was compared to a matching subgroup from an external control. Overall survival for recurrent high-grade glioma was 13.6 months (95% confidence interval, 10.8 to 20.0) and was statistically improved relative to an external control (hazard ratio, 0.45; P = 0.003). Tumor samples from subjects surviving more than 52 weeks after Toca 511 delivery disproportionately displayed a survival-related mRNA expression signature, identifying a potential molecular signature that may correlate with treatment-related survival rather than being prognostic. Toca 511 and Toca FC show excellent tolerability, with RRV persisting in the tumor and RRV control systemically. The favorable assessment of Toca 511 and Toca FC supports confirmation in a randomized phase 2/3 trial (NCT02414165).

1 December 2016 in Neurosurgery
Verified
Journal Article
Open access
PDF file
ILIan Lee
Ian Lee
SKSteven Kalkanis
Steven Kalkanis
CHConstantinos G. Hadjipanayis
Constantinos G. Hadjipanayis
BACKGROUND:. The value of maximal safe cytoreductive surgery in recurrent high-grade gliomas (HGGs) is gaining wider acceptance. However, patients may

1 February 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
DBDavid Boyce-Fappiano
David Boyce-Fappiano
EEErinma Elibe
Erinma Elibe
LSLonni Schultz
Lonni Schultz
SRSamuel Ryu
Samuel Ryu
MSM. Salim Siddiqui
M. Salim Siddiqui
FSFarzan Siddiqui
Farzan Siddiqui

25 February 2022 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
GHGrayson A Herrgott
Grayson A Herrgott
KAKaram P Asmaro
Karam P Asmaro
MWMichael Wells
Michael Wells
TSThais S Sabedot
Thais S Sabedot
TMTathiane M Malta
Tathiane M Malta
AnaValeria CastroAnaValeria Castro
AnaValeria Castro
Background: DNA methylation abnormalities are pervasive in pituitary neuroendocrine tumors (PitNETs). The feasibility to detect methylome alterations in circulating cell-free DNA (cfDNA) has been reported for several central nervous system (CNS) tumors but not across PitNETs. The aim of the study was to use the liquid biopsy (LB) approach to detect PitNET-specific methylation signatures to differentiate these tumors from other sellar diseases. Methods: We profiled the cfDNA methylome (EPIC array) of 59 serum and 41 plasma LB specimens from patients with PitNETs and other CNS diseases (sellar tumors and other pituitary non-neoplastic diseases, lower-grade gliomas, and skull-base meningiomas) or nontumor conditions, grouped as non-PitNET. Results: Our results indicated that despite quantitative and qualitative differences between serum and plasma cfDNA composition, both sources of LB showed that patients with PitNETs presented a distinct methylome landscape compared to non-PitNETs. In addition, LB methylomes captured epigenetic features reported in PitNET tissue and provided information about cell-type composition. Using LB-derived PitNETs-specific signatures as input to develop machine-learning predictive models, we generated scores that distinguished PitNETs from non-PitNETs conditions, including sellar tumor and non-neoplastic pituitary diseases, with accuracies above ~93% in independent cohort sets. Conclusions: Our results underpin the potential application of methylation-based LB profiling as a noninvasive approach to identify clinically relevant epigenetic markers to diagnose and potentially impact the prognostication and management of patients with PitNETs.

13 March 2018 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
RRRichard Rammo
Richard Rammo
KAKaram Asmaro
Karam Asmaro
LSLonni Schultz
Lonni Schultz
LSLisa Scarpace
Lisa Scarpace
SSSalim Siddiqui
Salim Siddiqui
ILIan Lee
Ian Lee

15 September 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
SHSameah A. Haider
Sameah A. Haider
KAKaram Asmaro
Karam Asmaro
SKSteven N. Kalkanis
Steven N. Kalkanis
ILIan Lee
Ian Lee
MBMichael Bazydlo
Michael Bazydlo
TWTobias Walbert
Tobias Walbert
Objective We aimed to characterize the socioeconomic impact of glioma for patients with clinical and radiographic evidence of disease stability, using the standardized Medical Expenditure Panel Survey–Household Component (MEPS-HC). Methods The MEPS-HC questionnaire was used to investigate the degree of economic hardship referable to the patient9s brain tumor and treatment. The questionnaire included demographic variables such as age at diagnosis, ethnicity, highest level of education, and annual household income. Descriptive statistics were used to characterize variables and between-group comparisons were evaluated using Fisher exact test. Results Of 127 prescreened patients, 89 of 107 eligible patients completed the survey. Pathology at diagnosis was predominantly low grade (60%). Most patients were insured at time of diagnosis (91%), married (76%), and employed (79%), with annual household incomes slightly higher than the national average. Despite this, nearly a quarter incurred debt referable to brain tumor care (24%), 53% required extended unpaid time off, and 46% retired or were no longer working. Financial burden and workforce morbidity were insensitive to tumor location, laterality, and annual household income. Patients with gross total resection at initial surgery were less likely to report ongoing limitations in daily activities (45% vs 83%, p = 0.004). Conclusions Even in a population of stable, high-functioning glioma survivors, financial burden and workforce morbidity was ubiquitous across all tumor subtypes, treatment paradigms, and income levels.